Update and overview of outpatient parenteral antimicrobial therapy regulations and reimbursement

Clinical Infectious Diseases

Volumn 51, Issue SUPPL. 2, 2010, Pages

  Nolet, Barbara Ross ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL THERAPY; DRUG FORMULARY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; MANAGED CARE; MEDICARE; OUTPATIENT CARE; OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; UNITED STATES;

AMBULATORY CARE; ANTI-BACTERIAL AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; MEDICARE; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 77957866251     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653522     Document Type: Review

References (16)

1. US Congress. Office of Technology Assessment. Home drug infusion therapy under Medicare. Chapter OTA-H-509. Washington, DC: US Government Printing Office, May 1992.
2. Tice AD, Hoaglund PA, Nolet B, et al. Cost perspectives for outpatient intravenous antimicrobial therapy. Pharmacotherapy 2002; 22(Suppl):63S-70S.
3. Department of Health and Human Services, Centers for Medicare & Medicaid Services. Medicare program: Medicare prescription drug benefit. Federal Register 2005; 79:4193-4742.
4. The Medicare Home Infusion Therapy Coverage Act of 2007 (HR 2567). http://www.idsociety.org/WorkArea/downloadasset.aspx?id=5750. Accessed 15 January 2010.
5. Department of Health and Human Services, Centers for Medicare & Medicaid Services. Medicare program: revisions to payment policies under the physician fee schedule, and other Part B payment policies for CY 2008; revisions to the payment policies of ambulance services under the ambulance fee schedules for CY 2008; and the amendment of the E-prescribing exemption for computer generated facsimile transmissions. Federal Register 2007; 72:66222-66578.
6. S.2499: Medicare, Medicaid, and SCHIP Extension Act of 2007. http://www.govtrack.us/congress/bill.xpd?bill=s110-2499. Accessed 15 January 2010.
7. Rosenthal MB, Landon BE, Normand S-LT, Frank RG, Epstein AM. Pay for performance in commercial HMOs. N Engl J Med 2006; 355:1855-1902.
8. Centers for Medicare & Medicaid Services. Hospital quality initiatives. http://www.cms.hhs.gov/HospitalQualityInits. Accessed 15 January 2010.
9. Centers for Medicare & Medicaid Services. US Department of Health and Human Services. Medicare hospital value-based purchasing options paper: 2nd public listening session, April 12, 2007. http://www.cms.hhs.gov// AcuteinpatientPPS/downloads/HospitalVBPOptions.pdf. Accessed 17 September 2009.
10. Overview: Physician Quality Reporting Initiative (PQRI). 2009. http://www.cms.gov/pqri. Accessed 15 January 2010.
11. US Department of Health and Human Services. Centers for Medicare & Medicaid Programs and Information. http://www.cms.hhs.gov. 19 July 2010.
12. Centers for Medicare & Medicaid Services. Competitive acquisition for Part B drugs & biologicals. http://www.cms.hhs.gov/ competitiveacquisforbios/. Accessed 15 January 2010.
13. Lace DA. The competitive acquisition program for drugs and biologicals. Manag Care 2006; 15(Suppl 3):21-24.
14. USP 797 Guidebook to pharmaceutical compounding - sterile preparations. In: USP Pharmacists Pharmacopeia 2008-2009. 2nd ed. Bethesda, MD: American Society of Health-System Pharmacists, 2008.
15. Manchikanti L, McMahon EB. Physician refer thyself: is Stark II, phase III the final voyage? Pain Physician 2007; 10:725-741.
16. Travis NL, Wool HS, Finnegan JH. New Stark phase III regulations: the impact and changes. J Am Coll Radiol 2008; 5:139-143.